Literature DB >> 23369681

International rare cancers initiative.

Nicola Keat1, Kate Law, Matthew Seymour, Jack Welch, Ted Trimble, Denis Lascombe, Anastassia Negrouk.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23369681     DOI： 10.1016/S1470-2045(12)70570-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  11 in total

1.  Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Authors:  Madhur K Garg; Fengmin Zhao; Joseph A Sparano; Joel Palefsky; Richard Whittington; Edith P Mitchell; Mary F Mulcahy; Karin I Armstrong; Nassim H Nabbout; Shalom Kalnicki; Bassel F El-Rayes; Adedayo A Onitilo; Daniel J Moriarty; Thomas J Fitzgerald; Al B Benson
Journal:  J Clin Oncol       Date:  2017-01-09       Impact factor: 44.544

Review 2.  The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers.

Authors:  Anne F Schott; John J Welch; Claire F Verschraegen; Razelle Kurzrock
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

Review 3.  Statistical genomics in rare cancer.

Authors:  Farnoosh Abbas-Aghababazadeh; Qianxing Mo; Brooke L Fridley
Journal:  Semin Cancer Biol       Date:  2019-08-19       Impact factor: 15.707

Review 4.  Small bowel adenocarcinomas--existing evidence and evolving paradigms.

Authors:  Kanwal Raghav; Michael J Overman
Journal:  Nat Rev Clin Oncol       Date:  2013-07-30       Impact factor: 66.675

5.  Pre-referral GP consultations in patients subsequently diagnosed with rarer cancers: a study of patient-reported data.

Authors:  Silvia C Mendonca; Gary A Abel; Georgios Lyratzopoulos
Journal:  Br J Gen Pract       Date:  2016-03       Impact factor: 5.386

Review 6.  Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks.

Authors:  Anthony McDonnell; John H Rex; Herman Goossens; Marc Bonten; Vance G Fowler; Aaron Dane
Journal:  Clin Infect Dis       Date:  2016-08-15       Impact factor: 9.079

Review 7.  Rare cancers: Challenges & issues.

Authors:  Raveendran K Pillai; K Jayasree
Journal:  Indian J Med Res       Date:  2017-01       Impact factor: 2.375

Review 8.  Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer.

Authors:  Manju D Chandrasegaram; Anthony J Gill; Jas Samra; Tim Price; John Chen; Jonathan Fawcett; Neil D Merrett
Journal:  World J Gastrointest Oncol       Date:  2017-10-15

9.  An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.

Authors:  Martin Gore; Allan Hackshaw; William E Brady; Richard T Penson; Richard Zaino; W Glenn McCluggage; Raji Ganesan; Nafisa Wilkinson; Timothy Perren; Ana Montes; Jeffrey Summers; Rosemary Lord; Graham Dark; Gordon Rustin; Melanie Mackean; Nicholas Reed; Sean Kehoe; Michael Frumovitz; Helen Christensen; Amanda Feeney; Jonathan Ledermann; David M Gershenson
Journal:  Gynecol Oncol       Date:  2019-04-18       Impact factor: 5.482

10.  Sample size calculation in randomised phase II selection trials using a margin of practical equivalence.

Authors:  Hakim-Moulay Dehbi; Allan Hackshaw
Journal:  Trials       Date:  2020-03-30       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.